Literature DB >> 2033266

Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.

S K Kochi1, R C Johnson, A P Dalmasso.   

Abstract

Lyme disease is a multisystemic illness caused by the spirochete Borrelia burgdorferi. In the absence of specific antibody, the spirochete is resistant to the bactericidal activity of C, despite the capacity of B. burgdorferi to activate both C pathways. We examined the mechanism of serum resistance by measuring the deposition of C3 and terminal C components on B. burgdorferi in the presence and absence of immune IgG. In normal human serum antibody-sensitized borreliae bound similar amounts of C3, and similar or increased amounts of C8 and C9, in comparison to unsensitized bacteria. However, at comparable levels of C3, C8, or C9 uptake, only sensitized bacteria were killed. The requirement of antibody for killing could not be explained by differences in the rate of C deposition or by differences in the C9 to C8 ratio in the membrane attack complex (MAC). We found that bacteria incubated in C5-depleted human serum, but not in C6-depleted serum, were killed when this treatment was followed by antibody and the missing C components. Bacteria were also killed by reactive lysis (C5b-9) provided that antibody was present. Therefore, the effect of bactericidal IgG occurred at the stage of C5b binding to the bacterial surface. Elution studies of bound C9 indicated that the MAC was stably bound to the outer membrane of B. burgdorferi, whether or not the bacteria were treated with antibody. However, treatment with 0.1% trypsin released 48% of 125I-C9 from the surface of unsensitized borreliae and 24% from IgG-sensitized cells, demonstrating that the presence of the antibody changed the accessibility to trypsin of C9 in the MAC. These results indicate that the effect of antibody in the killing process is not to enhance the rate or extent of initial or terminal component binding, but rather to alter the bacterial outer membrane to allow effective MAC formation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033266

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

2.  Identification of Borrelia burgdorferi outer surface proteins.

Authors:  Chad S Brooks; Santosh R Vuppala; Amy M Jett; Darrin R Akins
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Cryptic and exposed invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi sl.

Authors:  F T Liang; J M Nowling; M T Philipp
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

4.  Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present.

Authors:  M Solé; C Bantar; K Indest; Y Gu; R Ramamoorthy; R Coughlin; M T Philipp
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Decorin-binding protein of Borrelia burgdorferi is encoded within a two-gene operon and is protective in the murine model of Lyme borreliosis.

Authors:  K E Hagman; P Lahdenne; T G Popova; S F Porcella; D R Akins; J D Radolf; M V Norgard
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Nitric oxide production during murine Lyme disease: lack of involvement in host resistance or pathology.

Authors:  K P Seiler; Z Vavrin; E Eichwald; J B Hibbs; J J Weis
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Antigenic stability of Borrelia burgdorferi during chronic infections of immunocompetent mice.

Authors:  S W Barthold
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

9.  Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi.

Authors:  R K Straubinger; Y F Chang; R H Jacobson; M J Appel
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

10.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.